|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0006826,
umls-concept:C0021622,
umls-concept:C0025202,
umls-concept:C0029246,
umls-concept:C0030705,
umls-concept:C0035168,
umls-concept:C0087111,
umls-concept:C0205179,
umls-concept:C0239307,
umls-concept:C0278996,
umls-concept:C0282460,
umls-concept:C0439743,
umls-concept:C0442711,
umls-concept:C0444669,
umls-concept:C0678222,
umls-concept:C1140680,
umls-concept:C1261473,
umls-concept:C1516985,
umls-concept:C1579259,
umls-concept:C1706888,
umls-concept:C1882071,
umls-concept:C1999216,
umls-concept:C2348042
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2010-8-4
|
|
pubmed:abstractText |
BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
pubmed-author:AertsClaireC,
pubmed-author:AllgeierAnoukA,
pubmed-author:BlayJean-YvesJY,
pubmed-author:BogaertsJanJ,
pubmed-author:BrainEtienneE,
pubmed-author:De GreveJacquesJ,
pubmed-author:FontaineChristelC,
pubmed-author:FritschHolgerH,
pubmed-author:HanftGertraudG,
pubmed-author:LacombeDenisD,
pubmed-author:MachielsJean-PascalJP,
pubmed-author:MunzertGerdG,
pubmed-author:RapionJéromeJ,
pubmed-author:Ray-CoquardIsabelleI,
pubmed-author:SchöffskiPatrickP,
pubmed-author:SleijferStefanS,
pubmed-author:SoriaJean-CharlesJC,
pubmed-author:WolterPascalP
|
|
pubmed:copyrightInfo |
Copyright 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2206-15
|
|
pubmed:meshHeading |
pubmed-meshheading:20471824-Adult,
pubmed-meshheading:20471824-Aged,
pubmed-meshheading:20471824-Antineoplastic Agents,
pubmed-meshheading:20471824-Breast Neoplasms,
pubmed-meshheading:20471824-Feasibility Studies,
pubmed-meshheading:20471824-Female,
pubmed-meshheading:20471824-Head and Neck Neoplasms,
pubmed-meshheading:20471824-Humans,
pubmed-meshheading:20471824-Infusions, Intravenous,
pubmed-meshheading:20471824-Male,
pubmed-meshheading:20471824-Melanoma,
pubmed-meshheading:20471824-Middle Aged,
pubmed-meshheading:20471824-Neoplasms,
pubmed-meshheading:20471824-Ovarian Neoplasms,
pubmed-meshheading:20471824-Patient Compliance,
pubmed-meshheading:20471824-Pteridines,
pubmed-meshheading:20471824-Sarcoma,
pubmed-meshheading:20471824-Treatment Outcome,
pubmed-meshheading:20471824-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
|
|
pubmed:affiliation |
Department of General Medical Oncology, University Hospitals Leuven, Laboratory of Experimental Oncology, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium. patrick.schoffski@uzleuven.be
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
